Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Management of transplant rejection

Management (initiation, stabilisation and review of therapy)

Patient must have had an organ or tissue transplantation; AND

The treatment must be under the supervision and direction of a transplant unit.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Severe atopic dermatitis

Management (initiation, stabilisation and review of therapy)

Must be treated by a dermatologist; or

Must be treated by a clinical immunologist; AND

The condition must be ineffective to other systemic therapies; or

The condition must be inappropriate for other systemic therapies.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Severe psoriasis

Management (initiation, stabilisation and review of therapy)

The condition must be ineffective to other systemic therapies; or

The condition must be inappropriate for other systemic therapies; AND

The condition must have caused significant interference with quality of life; AND

Must be treated by a medical practitioner who is either: (i) a dermatologist, (ii) a rheumatologist, (iii) general physician; or

Must be treated by a medical practitioner in consultation with one of the above specialist types who is either an accredited: (i) dermatology registrar, (ii) rheumatology registrar.

For patients who do not demonstrate an adequate response to ciclosporin, a Psoriasis Area and Severity Index (PASI) assessment must be completed, preferably while on treatment, but no longer than 4 weeks following the cessation of treatment. This assessment will be required for patients who transition to 'biological medicines' for the treatment of 'severe chronic plaque psoriasis'.

This assessment must be documented in the patient's medical records.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Nephrotic syndrome

Management (initiation, stabilisation and review of therapy)

Patient must have failed prior treatment with steroids and cytostatic drugs; or

Patient must be intolerant to treatment with steroids and cytostatic drugs; or

The condition must be considered inappropriate for treatment with steroids and cytostatic drugs; AND

Patient must not have renal impairment; AND

Must be treated by a nephrologist.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Severe active rheumatoid arthritis

Management (initiation, stabilisation and review of therapy)

The condition must have been ineffective to prior treatment with classical slow-acting anti-rheumatic agents (including methotrexate); or

The condition must be considered inappropriate for treatment with slow-acting anti-rheumatic agents (including methotrexate); AND

Must be treated by a rheumatologist; or

Must be treated by a clinical immunologist.